🇺🇸 FDA

Company profile · Sponsor

ViiV

ViiV Healthcare BV

E76A7D4 · EMA pharma EU
Pipeline
10
Drugs
0
Patents
0

Quick answer

ViiV (E76A7D4) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E76A7D4
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (10)

Search pipeline →

  1. Dovato 50 mg/300 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets

    ViiV

    Human immunodeficiency virus (HIV)

    phase 3 small molecule active

    1 trial

  2. Dovato 50 mg/300 mg film-coated tablets, Dovato 50 mg/300 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Vocabria 400 mg prolonged-release suspension for injection, Vocabria 600 mg prolonged-release suspension for injection

    ViiV

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  3. Rukobia 600 mg prolonged-release tablets

    ViiV

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

  4. Vocabria 600 mg prolonged-release suspension for injection, REKAMBYS 900 mg prolonged-release suspension for injection

    ViiV

    HIV Infections

    phase 3 small molecule active

    1 trial

  5. Dovato 50 mg/300 mg film-coated tablets, Descovy 200 mg/25 mg film-coated tablets

    ViiV

    HIV Infections

    phase 2 small molecule active

    1 trial

  6. Placebo for GSK3739937 Tablets are tablets for oral administration and visually match the active GSK3739937 Tablets with the omission of the active ingredient. Placebo for GSK3739937 Tablets are white, round, film coated tablets containing no markings.

    ViiV

    HIV Infections

    phase 2 small molecule active

    1 trial

  7. Tablets are oval, biconvex, plain and white to off white, Placebo for GSK4011499 Tablets are tablets for oral administration. Tablets are oval, biconvex, plain, and white to off white.

    ViiV

    HIV Infections

    phase 2 small molecule active

    1 trial

  8. Visual match to product

    ViiV

    HIV Infections

    phase 2 small molecule active

    1 trial

  9. An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)

    ViiV

    HIV Infections

    phase 1 other active

    1 trial

  10. Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

    ViiV

    human immunodeficiency virus (HIV)

    phase 1 other active

    1 trial

Frequently asked questions

What is ViiV?

ViiV (E76A7D4) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does ViiV sponsor?

We track 10 ClinicalTrials.gov-linked programs for ViiV, including Dovato 50 mg/300 mg film-coated tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets and 9 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ViiV company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.